MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.50
-0.65
-3.58%
After Hours: 18.00 +0.5 +2.86% 17:51 01/26 EST
OPEN
18.00
PREV CLOSE
18.15
HIGH
18.38
LOW
17.35
VOLUME
383.04K
TURNOVER
--
52 WEEK HIGH
35.93
52 WEEK LOW
9.12
MARKET CAP
1.39B
P/E (TTM)
-7.8433
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Doing underway in Alector, AbbVie's study of AL002 in Alzheimer’s disease
The first participant has been dosed in Alector's (ALEC) INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early
Seekingalpha · 1d ago
Alector Announces First Participant Dosed In Phase 2 Study Evaluating AL002 In Individuals With Early Alzheimer's Disease
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer's Disease AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development Study
Benzinga · 1d ago
Alector's business chief steps down
Alector's (ALEC) chief business officer Sabah Oney, Ph.D., will be leaving the company to pursue other opportunities; Shehnaaz Suliman, M.D., MBA, M.Phil., president and COO will serve as interim CBO.Transition will be effective
Seekingalpha · 6d ago
*DJ Alector: Pres and Chief Operating Officer Shehnaaz Suliman to Serve as Interim CBO >ALEC
Dow Jones · 6d ago
*DJ Alector Announces Departure of Chief Business Officer Sabah Oney >ALEC
Dow Jones · 6d ago
Alector Announces Departure of Chief Business Officer
Sabah Oney steps down from a role held since January 2018; joined Alector in October 2016The departure will be effective February 1, 2021; will assist in transition until May 3, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, I...
GlobeNewswire · 6d ago
Press Release: Alector Announces Departure of Chief Business Officer
Dow Jones · 6d ago
Alector Chief Business Officer Sabah Oney to Depart
MT Newswires · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALEC. Analyze the recent business situations of Alector through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALEC stock price target is 32.13 with a high estimate of 41.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 191
Institutional Holdings: 53.59M
% Owned: 67.63%
Shares Outstanding: 79.24M
TypeInstitutionsShares
Increased
46
7.44M
New
64
-2.23M
Decreased
35
6.40M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Co-Founder/Director
Tillman Gerngross
President/Chief Operating Officer
Shehnaaz Suliman
Chief Executive Officer/Co-Founder/Director
Arnon Rosenthal
Vice President - Finance
Calvin Yu
Other
Robert King
Other
Sabah Oney
Other
Siang-Shu Robert
Other
Robert Paul
Lead Director/Independent Director
Louis Lavigne
Independent Director
Paula Hammond
Independent Director
Terry McGuire
Independent Director
Richard Scheller
Independent Director
David Wehner
Independent Director
Kristine Yaffe
  • Dividends
  • Splits
  • Insider Activity
No Data
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.